Biomedical subjects

T Takasago

Publications and source records attributed to T Takasago.

42 records · Page 3Linked to original sources

PubMed1991

Equivalent heart rate during ventricular fibrillation in the dog heart: mechanoenergetic analysis.

We propose equivalent heart rate (eHR) as an estimate of the frequency of contractions of individual myocytes in a fibrillating ventricle by analyzing mechanics and energetics of the ventricle. Using the isolated, cross-circulated dog heart preparation, we determined eHR in two different ways. First, we obtained eHR (eHR1) from myocardial O2 consumption (Vo2)-equivalent pressure-volume area (ePVA) data points during ventricular fibrillation (VF) by utilizing the Vo2-pressure-volume area (PVA) relation in the beating state. PVA is the area surrounded by the end-systolic and end-diastolic pressure-volume relations and the systolic pressure-volume trajectory in the pressure-volume diagram. PVA has been shown to represent the total mechanical energy generated by each contraction. We have recently proposed ePVA as a measure of the total mechanical energy generated by single contractions of all individual asynchronously contracting myocytes in a fibrillating ventricle. ePVA is the area surrounded by the horizontal line at the VF pressure and the end-systolic and end-diastolic pressure-volume relations in the beating state. Second, we measured Vo2 in beating state at various heart rates and Vo2 during VF under a mechanically unloaded condition. By comparing these fibrillating and beating Vo2 values, we determined eHR (eHR2) for the fibrillating state. eHR1 was 216 +/- 27 beats/min and eHR2 was 223 +/- 26 beats/min. These two values were not significantly different. We conclude that the average frequency of contractions of individual myocytes in a fibrillating ventricle is equivalent approximately to 220 beats/min in terms of ventricular energetics.

Animals↗

PubMed1991

[The effect of glycerol on local cerebral blood flow in patients with chronic ischemic cerebrovascular lesions].

The effect of glycerol on local cerebral blood flow was examined in patients with chronic ischemic cerebrovascular diseases (CVD). Twelve patients with minor completed stroke (10 cases) or transient ischemic attacks (2 cases) were subjected to the study (8 males, 4 females, the age ranging 27 to 70 with average of 56 +/- 15 years). Cerebral blood flow (CBF) was measured with stable xenon computerized tomography (Xe-CT). Each patient had 3 sequential Xe-CTs; resting, with intravenous administration of 200 ml of glycerol (group A) or lactated Ringer's solution (group B), and with intravenous administration of 1 g of acetazolamide. The resting CBF, CBF with glycerol, and CBF with acetazolamide were 30.4 +/- 1.6 ml/100 g/min (ml), 35.1 +/- 2.6 ml, 44.2 +/- 2.2 ml in group A, and 29.9 +/- 2.0 ml, 28.5 +/- 1.9 ml, 45.0 +/- 3.2 ml in group B, respectively. Glycerol increased CBF significantly in patients with chronic CVD, and seemed to be effective in ameliorating chronic low perfusion state in these patients.

Adult↗

PubMed1989

Cardiac ryanodine receptor is absent in type I slow skeletal muscle fibers: immunochemical and ryanodine binding studies.

Cardiac ryanodine receptor was purified from canine ventricle as a single polypeptide of Mr 400,000 by a stepwise sucrose density gradient centrifugation and heparin-Sepharose CL-4B column chromatography. The [3H]ryanodine binding capacity (Bmax) was 60-fold enriched from cardiac microsomes without a change in affinity for [3H]ryanodine. The purity of the final preparation was determined to be greater than 95% by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Using this purified preparation as an antigen, we produced six monoclonal antibodies which immunoprecipitated the cardiac ryanodine receptor. Three of these antibodies recognized the cardiac receptor on immunoblot analysis. In contrast, no protein in the microsomes isolated from Type I (slow) or Type II (fast) skeletal muscles was recognized by these antibodies. The [3H]ryanodine binding to cardiac and skeletal muscle microsomes was dependent on free Ca2+ concentration. In skeletal muscle microsomes, the [3H]ryanodine binding was remarkably enhanced by the addition of ATP or KCl and inhibited by high free Ca2+, whereas it was less sensitive to these agents in cardiac microsomes. All of these results clearly demonstrate that the cardiac ryanodine receptor is different from the skeletal muscle receptors and is not present even in Type I (slow) skeletal muscle fibers, in which cardiac isoforms of some of the muscle proteins are constitutively expressed.

Alkaloids↗

PubMed1989

Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase.

The phosphorylation of canine cardiac and skeletal muscle ryanodine receptors by the catalytic subunit of cAMP-dependent protein kinase has been studied. A high-molecular-weight protein (Mr 400,000) in cardiac microsomes was phosphorylated by the catalytic subunit of cAMP-dependent protein kinase. A monoclonal antibody against the cardiac ryanodine receptor immunoprecipitated this phosphoprotein. In contrast, high-molecular-weight proteins (Mr 400,000-450,000) in canine skeletal microsomes isolated from extensor carpi radialis (fast) or superficial digitalis flexor (slow) muscle fibers were not significantly phosphorylated. In agreement with these findings, the ryanodine receptor purified from cardiac microsomes was also phosphorylated by cAMP-dependent protein kinase. Phosphorylation of the cardiac ryanodine receptor in microsomal and purified preparations occurred at the ratio of about one mol per mol of ryanodine-binding site. Upon phosphorylation of the cardiac ryanodine receptor, the levels of [3H]ryanodine binding at saturating concentrations of this ligand increased by up to 30% in the presence of Ca2+ concentrations above 1 microM in both cardiac microsomes and the purified cardiac ryanodine receptor preparation. In contrast, the Ca2+ concentration dependence of [3H]ryanodine binding did not change significantly. These results suggest that phosphorylation of the ryanodine receptor by cAMP-dependent protein kinase may be an important regulatory mechanism for the calcium release channel function in the cardiac sarcoplasmic reticulum.

Animals↗

PubMedDate not supplied

Cerebrovascular reserve capacity in ischemia due to occlusion of a major arterial trunk: studies by Xe-CT and the acetazolamide test.

Classifications based on clinical and radiographic criteria have proved to be inadequate predictors of the course of cerebral ischemia or its response to therapy. In this study the cerebrovascular reserve capacity (CRC) of 46 patients with symptomatic cerebrovascular ischemia was studied by stable xenon-enhanced CT (Xe-CT) combined with the acetazolamide test. Fifteen patients had internal carotid artery (ICA) occlusion, 10 had ICA stenosis, 10 had middle cerebral artery (MCA) occlusion, and 11 had MCA stenosis. In the patients with chronic cerebral ischemia due to occlusive lesions of the ICA and MCA, the CRC was reduced most in those with MCA occlusion, followed, in descending order, by those with ICA stenosis, MCA stenosis, and ICA occlusion. Our results indicate that measurement of the CRC elucidates cerebral hemodynamic factors that cannot be detected by angiography in patients with chronic cerebral ischemia and that Xe-CT combined with the acetazolamide test is useful for this purpose.

Acetazolamide↗

PubMedDate not supplied

The wash-in/washout protocol in stable xenon CT cerebral blood flow studies.

PURPOSE: We conducted a comparative study to optimize the scanning and inhalation protocols for xenon CT cerebral blood flow (CBF) examination (Xe CT), with the aim of improving the practical performance of Xe CT as a routine clinical examination. MATERIALS AND METHODS: Four different inhalation protocols, including 3-min, 6-min, and 8-min wash-in protocols, and a 3-min wash-in/5-min washout protocol, were compared in five healthy volunteers. Each subject underwent two serial Xe CT examinations with an interval of 30 min between the first one (wash-in) and the second one (wash-in/washout). A computer simulation was also performed to support the results of the clinical study. The rate of success was calculated from our experience of 110 clinical cases examined with the wash-in/washout protocol over the last 9 months. RESULTS: The mean CBF values with 6-min and 8-min wash-in protocols were 59.0 and 59.5 mL/100-g brain per min in the thalamus, and 19.5 and 19.0 mL/100-g brain per min in the frontal white matter, respectively. The mean CBF values with 3-min wash-in/5-min washout protocol were 60.0 mL/100-g brain per min in the thalamus and 18.5 mL/100-g brain per min in the frontal white matter, respectively. Computer simulation showed improved signal-to-noise ratio by employing the 3-min wash-in/5-min washout protocol instead of 8-min wash-in protocol for the same number of data points. The rate of success improved to 99.1% due to the significant decrease in head motion with the shorter period of inhalation. CONCLUSION: A wash-in/washout protocol is a useful alternative in Xe CT CBF measurement and more useful than the wash-in method for clinical purposes.

Administration, Inhalation↗